lenalidomide: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
lenalidomide: clinical details
Prescribing considerations
- Treatment must be supervised by a clinician experienced in anticancer therapy.
- Complete Pregnancy Prevention Programme requirements and controlled-distribution documentation.
- Assess renal function because exposure rises as renal clearance falls.
- Assess thrombosis risk, infection risk, tumour burden and relevant companion-treatment toxicities.
- Establish hepatitis B status before treatment and consider specialist input for current or previous infection.
Contraindications and cautions
- Pregnancy.
- Childbearing potential unless every Pregnancy Prevention Programme condition is met.
- Hypersensitivity to lenalidomide or any excipient.
- Previous severe rash associated with thalidomide.
Monitoring
- Full blood count at baseline and regularly during treatment; act on neutropenia, thrombocytopenia or anaemia.
- Renal and liver function, including review after clinically important changes.
- Baseline and ongoing thyroid function.
- Pregnancy testing as required by the Pregnancy Prevention Programme.
- Monitor for infection, thrombosis, bleeding, severe skin reactions, tumour lysis or flare, secondary malignancy and new neurological symptoms.
- Consider visual monitoring, particularly during prolonged dexamethasone-containing treatment.
Clinical pharmacology
Lenalidomide binds cereblon and promotes degradation of transcription factors including Ikaros and Aiolos. Oral absorption is rapid, CYP metabolism is limited, and most active substance is excreted unchanged in urine; impaired renal function substantially increases exposure.
Formulation and product differences
- The selected product is a hard capsule containing lenalidomide as lenalidomide ammonium chloride.
- It contains lactose and is unsuitable for certain rare hereditary disorders of galactose or glucose-galactose handling.
- The capsule must remain intact. Pregnant people or those who may be pregnant should not handle the blister or capsule; caregivers and healthcare professionals should use disposable gloves.
lenalidomide preparations and strengths
Capsule
Route: Oral
Strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg
lenalidomide interactions
The specialist team should review all prescribed, over-the-counter and complementary treatments.
Warfarin
Closer anticoagulation monitoring is advised, particularly when dexamethasone is also used.
Digoxin
Lenalidomide may increase digoxin exposure, so blood-level monitoring may be needed.
Statins
Combined use may increase muscle injury or rhabdomyolysis risk, requiring clinical and laboratory monitoring.
Erythropoietic agents or hormone-replacement therapy
These may increase blood-clot risk, particularly with dexamethasone-containing treatment.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.